nach oben

Erschienen in:

29.11.2021

Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs)

verfasst von: Caterina Cusumano, Sébastien Carrere, Alix Bouillin, Stéphanie Nougaret, Lakhdar Khellaf, François Quénet, Olivia Sgarbura

Erschienen in: Surgical Endoscopy | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the best effective treatment for pseudomyxoma peritonei (PMP). In the last years, the advances in histopathology have stratified PMP lesions in different degrees of aggressivity suggesting the possibility of a tailored treatment. In a subset of patients with small volume peritoneal disease, laparoscopic CRS and HIPEC is feasible. The aim of this study is to analyze the results of laparoscopic CRS + HIPEC in a monocentric series of patients under patient-related experience measures (PREMs).

Methods

All consecutive patients who underwent laparoscopic CRS-HIPEC with curative intent at Cancer Institute of Montpellier were retrieved from a prospectively maintained database and analyzed. Selection criteria for laparoscopic approach were low-grade PMP with pathological confirmation prior to CRS-HIPEC, age < 75 years, no extra-peritoneal disease, peritoneal cancer index (PCI) < 10, and a limited history of abdominal surgery. A PREMS interview was conducted before analysis with all the included patients. Outcomes of interest included postoperative morbidity, medium-term survival, and PREMs.

Results

Fourteen patients were operated on for low-grade PMP with a laparoscopic approach at our institution. Conversions to laparotomy were necessary in three patients, and postoperative complications were observed in three patients (Clavien 3b in one patient). In-hospital postoperative median stay was 9.5 days. No death or recurrence was observed during the study period.

Conclusions

Laparoscopic CRS-HIPEC for LAMN in presence of small peritoneal disease is feasible in terms of postoperative morbidity and mortality. According to our PREMs questionnaire, patients' expectations were satisfied.

Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14(3):254–261. https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3%3c254::AID-SSU10%3e3.0.CO;2-UCrossRefPubMed

Benhaim L, Faron M, Gelli M, Sourrouille I, Honoré C, Delhorme J-B, Elias D, Goere D (2019) Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol 29:78–83. https://doi.org/10.1016/j.suronc.2019.03.004CrossRefPubMed

Rodríguez-Ortiz L, Arjona-Sánchez A, Ibañez-Rubio M, Sánchez-Hidalgo J, Casado-Adam A, Rufián-Peña S, Briceño-Delgado J (2020) Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surg Endosc. https://doi.org/10.1007/s00464-020-07572-xCrossRefPubMed

Dumont F, Duchalais E, Aumont A, Thibaudeau E (2020) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy by laparoscopy via a single-port approach for low-grade peritoneal malignancy. Surg Endosc 34(6):2789–2795. https://doi.org/10.1007/s00464-020-07492-wCrossRefPubMed

Abudeeb H, Selvasekar CR, O’Dwyer ST, Chakrabarty B, Malcolmson L, Renehan AG, Wilson MS, Aziz O (2020) Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms. Surg Endosc 34(12):5516–5521. https://doi.org/10.1007/s00464-019-07349-xCrossRefPubMedPubMedCentral

Mercier F, Jeremie G, Alyami M, Delphine V, Vahan K, Pascal R, Sylvie I, Guillaume P, Olivier G (2020) Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Surg Endosc 34(11):4916–4923. https://doi.org/10.1007/s00464-019-07280-1CrossRefPubMed

Sgarbura O, Al Hosni M, Petruzziello A, Figueroa R, Khellaf L, Pissas MH, Carrère S, Nougaret S, Bibeau F, Quénet F (2020) Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept. Int J Hyperth 37(1):585–591. https://doi.org/10.1080/02656736.2020.1772511CrossRef

Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, Hingh IHJTD, Moran BJ, der Speeten KV, Deraco M, Glehen O, Barrios-Sanchez P, Baumgartner JM, Ben-Yaacov A, Bertulli R, Cashin P, Cecil T, Dayal S, Simone MD, Foster JM, Yu Y (2020) Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.02.011CrossRefPubMed

Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly F-N, Glehen O, Cotte E (2014) Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol 40(5):529–535. https://doi.org/10.1016/j.ejso.2013.11.019CrossRefPubMed

10.

Rudolph C, Petersen GS, Pritzkuleit R, Storm H, Katalinic A (2019) The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany. BMC Health Serv Res 19(1):786. https://doi.org/10.1186/s12913-019-4646-4CrossRefPubMedPubMedCentral

11.

Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, Gilly FN, Network RENAPE (2017) The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis 12(1):37. https://doi.org/10.1186/s13023-017-0571-yCrossRefPubMedPubMedCentral

12.

Sugarbaker PH (2005) Cytoreductive surgery and perioperative intraperitoneal chemotherapy: a new standard of care for appendiceal mucinous tumors with peritoneal dissemination. Clin Colon Rectal Surg 18(03):204–214. https://doi.org/10.1055/s-2005-916281CrossRefPubMedPubMedCentral

13.

Taibi A, Geyl S, Salle H, Salle L, Mathonnet M, Usseglio J, Durand Fontanier S (2020) Systematic review of patient reported outcomes (PROs) and quality of life measures after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Oncol 35:97–105. https://doi.org/10.1016/j.suronc.2020.08.012CrossRefPubMed

14.

Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ, PSIGI (2020) Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.02.012CrossRefPubMed

15.

McDonald JR, O’Dwyer ST, Rout S, Chakrabarty B, Sikand K, Fulford PE, Wilson MS, Renehan AG (2012) Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg 99(7):987–992. https://doi.org/10.1002/bjs.8739CrossRefPubMed

16.

Guaglio M, Sinukumar S, Kusamura S, Milione M, Pietrantonio F, Battaglia L, Guadagni S, Baratti D, Deraco M (2018) Clinical surveillance after macroscopically complete surgery for low-grade appendiceal mucinous neoplasms (LAMN) with or without limited peritoneal spread: long-term results in a prospective series. Ann Surg Oncol 25(4):878–884. https://doi.org/10.1245/s10434-017-6305-5CrossRefPubMed

17.

Foster JM, Sleightholm RL, Wahlmeier S, Loggie B, Sharma P, Patel A (2016) Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis. World J Surg Oncol 14(1):243. https://doi.org/10.1186/s12957-016-0996-0CrossRefPubMedPubMedCentral

18.

Honoré C, Caruso F, Dartigues P, Benhaim L, Chirica M, Goéré D, Elias D (2015) Strategies for preventing pseudomyxoma peritonei after resection of a mucinous neoplasm of the appendix. Anticancer Res 35(9):4943–4947PubMed

19.

Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen H-C, Overman M, Raghav K, Eng C, Mansfield P, Royal R (2017) Low-grade appendiceal mucinous neoplasm of uncertain malignant potential (LAMN-UMP): prognostic factors and implications for treatment and follow-up. Ann Surg Oncol 24(1):187–193. https://doi.org/10.1245/s10434-016-5588-2CrossRefPubMed

20.

Esquivel J, Averbach A (2012) Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin [clinical study]. Gastroenterol Res Pract. https://doi.org/10.1155/2012/981245CrossRefPubMedPubMedCentral

21.

Arjona-Sanchez A, Esquivel J, Glehen O, Passot G, Turaga KK, Labow D, Rufian-Peña S, Morales R, van der Speeten K (2019) A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis. Surg Endosc 33(3):854–860. https://doi.org/10.1007/s00464-018-6352-4CrossRefPubMed

22.

Arjona-Sánchez A, Cortés-Guiral D, Duran-Martínez M, Villarejo-Campos P, Sánchez-Hidalgo JM, Casado-Adam A, Rodriguez-Ortiz L, Romero-Ruiz A, Rufian-Andujar B, Espinosa-Redondo E, Valenzuela-Molina F, Rufián-Peña S, Briceño-Delgado J (2020) Complete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy. Tech Coloproctol 24(10):1083–1088. https://doi.org/10.1007/s10151-020-02277-8CrossRefPubMed

23.

Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, Sardi A, Glehen O, Deraco M, Peritoneal Surface Oncology Group International (PSOGI) (2014) Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br J Surg 101(13):1758–1765. https://doi.org/10.1002/bjs.9674CrossRefPubMed

24.

Noiret B, Clement G, Lenne X, Bruandet A, Glehen O, Voron T, Piessen G, Eveno C (2020) Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national french practice. Ann Surg 272(5):847–854. https://doi.org/10.1097/SLA.0000000000004326CrossRefPubMed

25.

Arjona-Sanchez A, Aziz O, Passot G, Salti G, Esquivel J, Van der Speeten K, Piso P, Nedeclut S, Sommariva A, Yonemura Y, Turaga K, Selvasekar CR, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Casado-Adam A, Rufian-Peña S, Briceño J, Glehen O (2020) Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis The PSOGI international collaborative registry. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.11.140CrossRefPubMed

26.

Passot G, Dumont F, Goéré D, Arvieux C, Rousset P, Regimbeau J-M, Elias D, Villeneuve L, Glehen O, BIG-RENAPE Surgery Working Group (2018) Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE). The Br J Surg 105(6):663–667. https://doi.org/10.1002/bjs.10723CrossRefPubMed

27.

Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IHJT, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Morris DL (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30(20):2449–2456. https://doi.org/10.1200/JCO.2011.39.7166CrossRefPubMed

28.

Leimkühler M, Hentzen JEKR, Hemmer PHJ, Been LB, van Ginkel RJ, Kruijff S, van Leeuwen BL, de Bock GH (2020) Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 27(10):3973–3983. https://doi.org/10.1245/s10434-020-08379-9CrossRefPubMedPubMedCentral

29.

Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G (2020) Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part I: preoperative and intraoperative management. Eur J Surg Oncol 46(12):2292–2310. https://doi.org/10.1016/j.ejso.2020.07.041CrossRefPubMed

30.

Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G (2020) Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part II: postoperative management and special considerations. Eur J Surg Oncol 46(12):2311–2323. https://doi.org/10.1016/j.ejso.2020.08.006CrossRefPubMed

31.

Sheehan LA, Mehta AM, Sawan S, Dayal SP, Mohamed F, Moran BJ, Cecil TD (2017) Preserving fertility in pseudomyxoma peritonei, a novel approach. Pleura Peritoneum 2(1):33–36. https://doi.org/10.1515/pp-2016-0024CrossRefPubMedPubMedCentral

32.

Ortega-Deballon P, Glehen O, Levine E, Piso P, Sugarbaker PH, Hayes-Jordan A, Facy A, Bakrin N, Rat P (2011) Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey. Ann Surg Oncol 18(8):2297–2301. https://doi.org/10.1245/s10434-011-1595-5CrossRefPubMedPubMedCentral

33.

Kepenekian V, Péron J, Goéré D, Sgarbura O, Delhorme JB, Eveno C, Benzerdjeb N, Bonnefoy I, Villeneuve L, Rousset P, Abboud K, Pocard M, Glehen O (2021) Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: results from a large multicentric cohort. Int J Hyperthermia 38(1):805–814. https://doi.org/10.1080/02656736.2021.1903585CrossRefPubMed

Titel: Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs)
verfasst von: Caterina Cusumano
Sébastien Carrere
Alix Bouillin
Stéphanie Nougaret
Lakhdar Khellaf
François Quénet
Olivia Sgarbura
Publikationsdatum: 29.11.2021
Verlag: Springer US
Erschienen in: Surgical Endoscopy / Ausgabe 7/2022
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-021-08816-0

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs)